Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Despite several treatment options and an initial high response rate to androgen deprivation therapy, the majority of prostate cancers will eventually become castration-resistant in the metastatic stage (mCRPC). Androgen receptor splice variant 7 (ARV7) is one of the best-characterized androgen recep...
Main Authors: | Ivana Bratic Hench, Richard Cathomas, Luigi Costa, Natalie Fischer, Silke Gillessen, Jürgen Hench, Thomas Hermanns, Eloïse Kremer, Walter Mingrone, Ricardo Pereira Mestre, Heike Püschel, Christian Rothermundt, Christian Ruiz, Markus Tolnay, Philippe Von Burg, Lukas Bubendorf, Tatjana Vlajnic |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/8/1099 |
Similar Items
-
Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
by: Bram De Laere, et al.
Published: (2021-03-01) -
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
by: Joshua P. Schiff, et al.
Published: (2019-05-01) -
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01) -
Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
by: Moran Gadot, et al.
Published: (2020-04-01) -
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
by: Fatima Karzai, et al.
Published: (2018-12-01)